The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationPineda-Roman, M., Zangari, M., van Rhee, F., Anaissie, E., Szymonifka, J., Hoering, A., Petty, N., Crowley, J., Shaughnessy, J., Epstein, J., et al. (2008) · Leukemia · doi:10.1038/leu.2008.99 · Cited by 139 · cited 1×
“However, the value of the depth of response in the relapse setting has been subject to far less investigation than in the up-front setting.(7-11) In fact, there are few data exploring different outcomes between patients achieving very good partial response (VGPR) or complete response (CR) with salvage therapy,(7-11) a…”
Background
Cited by
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationMultiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002827 · Cited by 431
Self-citationDepth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
Lahuerta, J.-J., Paiva, B., Vidriales, M.-B., Cordón, L., Cedena, M.-T., Puig, N., Martinez-Lopez, J., Rosiñol, L., Gutierrez, N. C., Martín-Ramos, M.-L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2517 · Cited by 317
Self-citationNew criteria for response assessment: role of minimal residual disease in multiple myeloma
Paiva, B., van Dongen, J. J. M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2014-11-568907 · Cited by 299
Self-citation
Metadata
- Authors
- Paiva, B., Chandia, M., Puig, N., Vidriales, M.-B., Perez, J. J., Lopez-Corral, L., Ocio, E. M., Garcia-Sanz, R., Gutierrez, N. C., Jimenez-Ubieto, A., Lahuerta, J.-J., Mateos, M.-V., & San Miguel, J. F.
- Venue
- Haematologica
- Published
- 2014-11-07
- Volume
- 100
- Issue
- 2
- Pages
- e53-e55
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2003819112
- Cited by
- 53
- References
- 2
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. https://app.cochat.ai/papers/10.3324/haematol.2014.115162
- The paper
- Paiva, B., Chandia, M., Puig, N., Vidriales, M.-B., Perez, J. J., Lopez-Corral, L., Ocio, E. M., Garcia-Sanz, R., Gutierrez, N. C., Jimenez-Ubieto, A., Lahuerta, J.-J., Mateos, M.-V., & San Miguel, J. F. (2015). The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma. Haematologica. https://doi.org/10.3324/haematol.2014.115162
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.